


FORM PTO-1390 (REV. 12-2001)  TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER  65959/16
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)  <b>10/049804</b>	
INTERNATIONAL APPLICATION NO.  PCT/EP00/07736	INTERNATIONAL FILING DATE  August 9, 2000	PRIORITY DATE CLAIMED  August 16, 1999	
TITLE OF INVENTION  PREPARATION OF METAL OXIDE SUPPORTS LOADED WITH BIOMOLECULES			
APPLICANT(S) FOR DO/EO/US  F. Venema			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ul> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ul> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
<p><b>Items 11 to 20 below concern document(s) or information included:</b></p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</p> <p>14. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information:</p> <ul style="list-style-type: none"> <li>- paper copy of sequence listing;</li> <li>- statement that sequence listing adds no new matter; and</li> <li>- statement that paper and CRF forms of sequence listing are identical.</li> </ul>			

U.S. APPLICATION NO. OR KIN. NO. (See 37 CFR 1.65)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER		
<b>10/049804</b>	PCT/EP00/07736	65959/16		
21. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY		
<b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b>				
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO . . . . .		<b>\$1040.00</b>		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO . . . . .		<b>\$890.00</b>		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . . .		<b>\$740.00</b>		
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) . . . . .		<b>\$710.00</b>		
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) . . . . .		<b>\$100.00</b>		
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		\$ 890.00		
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	22 - 20 =	2	x \$18.00	\$ 36.00
Independent claims	3 - 3 =	0	x \$84.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$280.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$		
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		\$		
<b>SUBTOTAL =</b>		<b>\$ 926.00</b>		
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$		
<b>TOTAL NATIONAL FEE =</b>		\$		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +		\$		
<b>TOTAL FEES ENCLOSED =</b>		<b>\$ 926.00</b>		
		Amount to be refunded: \$		
		charged: \$		
<p>a. <input checked="" type="checkbox"/> A check in the amount of <b>\$ 926.00</b> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>01-1785</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.</p>				
<p><b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b></p>				
SEND ALL CORRESPONDENCE TO:				
<p>Craig J. Arnold, Esq. Amster, Rothstein &amp; Ebenstein 90 Park Avenue New York, NY 10016</p>				
<p>          SIGNATURE  <b>Elie H. Gendloff</b>          NAME  <b>44,704</b>          REGISTRATION NUMBER       </p>				



AR&amp;E Docket No. 65959/16

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : F. Venema  
 Serial No. : 10/049,804  
 I.A. Filing Date : February 14, 2002  
 For : PREPARATION OF METAL OXIDE SUPPORTS  
       : LOADED WITH BIOMOLECULES  
 Examiner : Unknown  
 Group Art Unit : Unknown


SUBMISSION OF CORRECTED SEQUENCE LISTING

U.S. Patent and Trademark Office  
 Box SEQUENCE  
 Room 1B03-Mailroom  
 Crystal Plaza Two  
 2011 South Clark Place  
 Arlington, VA 22202

"Express Mail" mailing label No. FL 777785128 US

Date of Deposit: July 26, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.  
 Name: Elie H. Gendloff

Signature: 

Sir:

Enclosed herewith is a corrected Sequence Listing in both paper and computer-readable form for the above-identified application. This submission was required in the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) dated April 29, 2002 (copy enclosed) in the above-identified case and is being filed concurrently with a reply to that Notification, along with a request for one-month extension of time and a check for the appropriate fees.

Applicant : F. Venema  
Serial No. : 10/049,804  
I.A. Filing Date : February 14, 2002  
Page 2

I hereby state that the information recorded in computer readable form is identical to the paper form of the Sequence Listing. Additionally, this Sequence Listing includes no new matter. Entry of the Sequence Listing is therefore respectfully requested.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 697-5995

Dated: New York, New York  
July 26, 2002

By: Elie H. Gendloff  
Elie H. Gendloff  
Registration No.: 44,704

65959/16

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : F. Venema  
Serial No. : Unknown  
Filed : Herewith  
For : PREPARATION OF METAL OXIDE SUPPORTS LOADED WITH BIOMOLECULES  
Examiner : Unknown  
Group Art Unit : Unknown

"Express Mail" mailing label No. EL 900663622 US  
Date of Deposit: February 14, 2002  
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.  
Name: Elie H. Gendloff  
Signature: *Elie H. Gendloff*

PRELIMINARY AMENDMENT ACCOMPANYING FILING UNDER 35 U.S.C. 371

Commissioner for Patents  
Washington, D.C. 20231

Sir:

The following amendments accompany the U.S. national stage filing of PCT/EP00/07736. The amendments to claims 1-2 were originally submitted under PCT Article 19, and the amendments to claims 16 and 17, together with the addition of claims 20-22, are submitted to eliminate the multiple dependencies of claims 3, 16 and 17, and the improper "use" claim of claim 16. The multiple dependency of claim 3 was added as an Article 19 amendment. Claim 3 is also amended to recite a preferred acidic solution.

Applicants also provide herewith a sequence listing, in both computer readable and paper form. The enclosed sequence listing does not go beyond the original disclosure in the international application as filed. Also, the information recorded in computer readable form is identical to the written sequence listing.

Applicant : F. Venema

Serial No. : Unknown

Filed : Herewith

Page 2

Amendment

IN THE SPECIFICATION:

Please add the following paragraph on page 1, immediately after the title.

--This application claims priority to PCT/EP00/07736, filed August 9, 2000, which claims priority to European Patent Application 99202649.2, filed August 16, 1999.--

Please amend claims 1-3, 16 and 17 to read as follows.

1. (Amended) A method for removing non-loaded amino groups which form part of the silanating agent used to activate a metal oxide surface during the preparation of metal oxide supports loaded with biomolecules, comprising the steps of:

- (a) activating the surface of the support by means of a silanating agent comprising an amine group;
- (b) loading the support by attaching biomolecules to the activated surface; and
- (c) treating said loaded support with an acidic solution.

2. (Amended) A method for removing non-loaded amino groups which form part of the silanating agent used to activate a metal oxide surface during the preparation of metal oxide supports loaded with biomolecules, comprising the steps of:

- (a) activating the surface of the support by means of a silanating agent comprising an amine group;
- (b) loading the support by attaching biomolecules to the activated surface; and
- (c) treating said loaded support with a basic or neutral solution.

3. (Amended) The method of claim 1, wherein the solution is of pH 2 to 6.

Applicant : F. Venema  
Serial No. : Unknown  
Filed : Herewith  
Page 3

16. (Amended) The metal oxide support of claim 14, suitable for performing a probe-based assay.

17. (Amended) A kit comprising the metal oxide support of claim 14, further comprising a detection means for determining whether binding has occurred between the biomolecules and an analyte.

Please add the following new claims 20-22.

20. (New) The method of claim 2, wherein the solution is pH 6-7.

21. (New) The metal oxide support of claim 15, suitable for performing a probe-based assay.

22. (New) A kit comprising the metal oxide support of claim 15, further comprising a detection means for determining whether binding has occurred between the biomolecules and an analyte.

Remarks

This application has 22 claims, including amended claims 1-3, 16 and 17, and new claims 20-22. The claim amendments are solely to make the claims more consistent with U.S. practice. As such, the claims as amended are fully supported by the specification as originally filed. Additionally, any narrowing claim amendments made herewith are not made for purposes of patentability, but rather to make the claims consistent with U.S. patent practice and to eliminate multiple dependencies to avoid the

Applicant : F. Venema  
Serial No. : Unknown  
Filed : Herewith  
Page 4

fees for filing multiple dependent claims.

The specification is also amended to provide priority information in the first paragraph of the application, as required under U.S. patent law.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 697-5995

Dated: New York, New York  
February 14, 2002

By: Elie H. Gendloff  
Elie H. Gendloff  
Registration No.: 44,704

Appendix - Marked up Claim Amendments

U.S. National Stage of PCT/EP00/07736

Additions are underlined and deletions are bracketed.

1. (Amended) A method for removing non-loaded amino groups which form part of the silanating agent used to activate a metal oxide surface during the preparation of metal oxide supports loaded with biomolecules, comprising the steps of:

(a) activating the surface of the support by means of a silanating agent comprising an amine group;

(b) loading the support by attaching biomolecules to the activated surface; and

(c) treating said [characterized in that subsequently the]loaded support [is treated]with an acidic solution[ and provided that the method is not used for the preparation of silica wafers which are aminated by silanation using (3-aminopropyl)monoethoxydimethylsilane and loaded with oligonucleotides].

2. (Amended) A method for removing non-loaded amino groups which form part of the silanating agent used to activate a metal oxide surface during the preparation of metal oxide supports loaded with biomolecules, comprising the steps of:

(a) activating the surface of the support by means of a silanating agent comprising an amine group;

(b) loading the support by attaching biomolecules to the activated surface[,]; and

(c) treating said [characterized in that subsequently the]loaded support [is treated]with a basic or neutral solution[ and provided that the method is not used for derivatization of aluminimoxide nanoparticles aminated with (3-aminopropyl)triethoxysilane, wherein the basic solution further contains a large excess of N-acetylhomocysteinelactone].

3. (Twice Amended) The method of claim 1[or 2], wherein the solution is of pH 2 to 6[7].

Appendix  
Page 2

16. (Amended) A kit [of parts]comprising the metal oxide support of claim 14[or 15], further comprising a detection means for determining whether binding has occurred between the biomolecules and an analyte.

10/049804

JC13 Rec'd PCT/PTO 14 FEB 2002

Untitled.ST25.txt  
SEQUENCE LISTING

<110> PAMGENE B.V.  
<120> Preparation of metal oxide supports loaded with biomolecules  
<130> PAM-003-PCT  
<140> PCT/EP00/07736  
<141> 2000-08-09  
<150> EP 99202649.2  
<151> 1999-08-16  
<160> 3  
<170> PatentIn version 3.1  
<210> 1  
<211> 30  
<212> DNA  
<213> Synthetic  
<220>  
<221> misc\_feature  
<223> probe

<400> 1 30  
tatggctctc ccgggagggg gggtccttggaa

<210> 2  
<211> 21  
<212> DNA  
<213> Synthetic  
<220>  
<221> misc\_feature  
<223> probe

<400> 2 21  
ttgtacagaa ctggaaaaagg a

<210> 3  
<211> 21  
<212> DNA  
<213> Artificial  
<220>  
<221> misc\_feature  
<223> probe

<400> 3 21  
tcctttcca gttctgtaca a

PREPARATION OF METAL OXIDE SUPPORTS LOADED WITH BIOMOLECULES

The invention relates to a method for the preparation of metal oxide supports loaded with biomolecules, to the thus obtained metal oxide supports, to the use of said supports for performing probe-based assays and to a kit of parts comprising said support and a detection means.

The present invention specifically relates to a method for the preparation of metal oxide supports loaded with biomolecules, comprising the steps of: (a) activating the surface of the support by means of an silanating agent comprising an amine group; and (b) loading the support by attaching biomolecules to the activated surface.

Such a method is known, e.g. from WO 99/002266, in which method aluminium oxide membranes are activated using 3-aminopropyl triethoxysilane (APS) after which oligonucleotide probes are covalently coupled to the activated membranes. A similar method is described for aluminiumoxide nanoparticles carrying antigens (Bioconjugate Chem. 1997, 8, 424-433). Further, for chromatographic purposes, aluminium oxide supports were used for covalent immobilization of concavalin A, after previous activation with APS (Biotechnology and Applied Biochemistry 16, 221-227 (1992)). Balladur et al., J. of Colloid and Interface Science, 194, 408-418, 1997 describe the adsorption of oligonucleotides on aminopropyl silane-modified silica wafers. These and similarly loaded metal oxide supports are thus useful for instance in probe-based assays, further for carrying biomolecules, e.g. for use as vaccines, and for separating other substances from mixtures by hybridizing, binding or interacting otherwise with those other substances.

A disadvantage of such supports is that a number of amino-groups of the silanating agent comprising an amine group used for the activation of the metal oxide surface, are still present as unloaded amino-groups even after the support has been loaded with the appropriate biomolecule. This may result in unwanted interactions (non-specific or a-specific interactions) of these amino-groups with various substances present in the medium in which the loaded support is used. For example, when used in probe-based assays, such a-specific interactions may generate high background signals disturbing the signals of the analyte, bound to the capture-biomolecules.

WO 01/12846

PCT/EP00/07736

2

It has now been found that when the method of the invention is applied, the non-loaded amino-groups are removed selectively from the surface of the further loaded support without affecting the loaded part of the surface.

The invention thus relates a method for the preparation of metal oxide supports loaded with biomolecules, comprising the steps of: (a) activating the surface of the support by means of a silanating agent comprising an amine group; (b) loading the support by attaching biomolecules to the activated surface, characterized in that subsequently the loaded support is treated with an acidic solution, and provided that the method is not used for the preparation of silica wafers which are aminated by silanation using (3-aminopropyl)monoethoxydimethylsilane, and loaded with oligonucleotides. Such loaded silica wafers have been subject to a study regarding the effect of pH on the maximum adsorbed amount of oligonucleotides onto the aminated silica wafer [Balladur et al., J. of Colloid and Interface Science, 194, 408-418, 1997]. Therefore this invention does not relate to (a method for the preparation of) such silica wafers.

According to another embodiment of the invention the activated and loaded support is subsequently treated with a basic solution (preferably for a prolonged period of time), provided that the method is not used for derivatization of aluminiumoxide nanoparticles aminated with (3-aminopropyl)triethoxysilane, wherein the basic solution further contains a large excess of N-acetylhomocysteinolactone. Such derivatized aluminiumoxide nanoparticles were prepared without the intention to remove aminogroups (Bioconjugate Chem. 1997, 8, 424-433) and are not an embodiment of the present invention (nor is the method for their preparation).

According to another embodiment of the invention the activated and loaded support is subsequently treated with a neutral solution (preferably for a prolonged period of time).

The usual methods for suppressing a-specific interactions of unloaded amino-groups on different types of supports involve chemical "capping" / "blocking" the unloaded amino-groups or prehybridizing them with DNA (see for example: Science, Vol. 270, 1995, 467-470; Nucleic Acids Research, Vol. 15 (13) 1987, 5353--5373; Nucleic Acids Research, Vol. 26 (17) 1998, 3883-3891, etc.). However, those methods are not very well defined and require more difficult procedures. Furthermore, with those methods the unloaded amino-groups are not actually removed from the surface, which is the case when the method of the present invention is applied.

WO 01/12846

PCT/EP00/07736

The method of the invention is well defined and easy to perform and the results, e.g. in terms of signal/background ratio's, are comparable or even better when compared to the usual procedures.

- 5 In any situation in which unloaded amino-groups are to be selectively removed from metal oxide supports loaded with biomolecules, the method of the present invention is applicable, provided that a silanating agent comprising an amine group has been used to activate the metal oxide surface.
- 10 The pH value of the solution with which the loaded supports may be treated according to the invention, depends substantially on the type of biomolecule attached to the surface and on the way of attaching (loading) the biomolecules to the surface, either covalently or adsorptively. When the biomolecule is attached to the surface covalently (i.e. they are attached to the amino-groups on the surface via some chemical linkage) and it can withstand both acidic and basic conditions, both acidic and basic solutions may be used for the removal of unloaded amino-groups. If the biomolecule is sensitive to either acidic or basic conditions, respectively a basic or acidic solution must be chosen for the removal of the unloaded amino-groups.
- 15 When adsorptively attached (i.e. the biomolecule adheres to the surface modified with a silanating agent comprising an amine group), also the overall charge of the biomolecule is a relevant parameter. For example, when a negatively charged biomolecule is adsorptively attached to the activated surface of the metal oxide support, it may become detached at a certain pH when the charge of either the biomolecule is reduced by protonation or the charge of the surface is reduced due to deprotonation. For example, an oligonucleotide having a negatively charged backbone will be protonated at very low pH values and it will subsequently be released from the positively charged activated surface of the support. Similarly, the loaded amino-groups are deprotonated at very high pH values (e.g. 11.5) resulting in the release of the negatively charged oligonucleotide.
- 20 A person skilled in the art will know how to find the balance between effective removal of the unloaded amino-groups and the intactness of the loaded support. Some preliminary experimentation may be required to find the optimal conditions for the specific circumstances.
- 25 However, use of an acidic solution is preferred, since the removal of unloaded amino-groups
- 30

WO 01/12846

PCT/EP00/07736

4

takes place much more rapidly than in basic conditions. At very low pH values it may even occur almost instantaneously (if the circumstances allow to use such a solution). Preferred are solutions with a pH 2 to 7. For surfaces to which oligonucleotides are attached a solution of pH 4-5 is particularly preferred.

5 The treatment with a neutral or basic solution is also effective, but requires longer treatment periods. The applicable pH range for a certain situation depends on the reagent used to coat the surface. The pKa of the amine groups influences the charge on the surface and thus the pH at which biomolecules, especially adsorbed biomolecules, stay attached to said surface. Of course the charge distribution on the biomolecules is also important. As explained above, depending on 10 their negative charge, biomolecules may become detached when the pH is very low. The treatment may take several hours up to about a day, depending on the pH value of the solution, the type of metal oxide of the support and the type of reagent used to activate the surface of the support.

15 The acid- or base-treatment time is not very critical in terms that the performance of the loaded support is not significantly affected after long treatment periods. Also the temperature at which the method may be performed is not very critical. However, temperatures up to 40 °C are preferred. Most preferably the method is applied at room temperature (18 - 24 °C).

20 Suitable (acidic or basic) solutions for use in the method according to the invention are aqueous buffered solutions adjusted to the desired pH value, for example, but not limited to, for acidic solutions: acetate buffers, phosphate buffers, citric acid buffers, and the like, for basic solutions: disodium hydrogen phosphate or sodium phosphate buffers, sodium tetraborate buffers, tris-buffers, diethanolamine/hydrogen chloride buffers, carbonate buffers, and the like. Appropriate buffers have a concentration of 40 mM, but also other concentrations may very well be applicable.

25

Metal oxide supports which may be used in the method of the invention are supports of metal oxides of, for example and not limited to, tantalum, titanium and aluminium, silicium as well as alloys of two or more metals and doped metals and alloys. Particularly useful supports are (electrochemically manufactured) porous metal oxide membranes. A preferred metal oxide is 30 aluminium oxide. Preferred porous metal oxide membranes are the membranes mentioned in WO 99/02266.

WO 01/12846

PCT/EP00/07736

5

The surface of the metal oxide support may be activated using different types of silanating agent comprising an amine group. Effective activating reagents are for example 3-aminopropyl triethoxysilane, 4-aminobutyl-dimethyl-methoxysilane, 3-[2-(2-aminoethylamino)ethylamino]-propyltrimethoxysilane, 3-(2-aminoethylamino)propyl-methyldimethoxysilane, 3-(2-aminoethylamino)propyltrimethoxysilane, 3-aminopropyl-methyl-diethoxysilane, (3-aminopropyl)-tris[2-(2-methoxyethoxy)ethoxy]silane and 4-aminobutyltriethoxysilane, however also other silanating agents comprising an amine group may be equally suitable. A preferred silanating agent is aminopropyl triethoxysilane (APS) used in an unbuffered aqueous solution.

10 The silanation reaction may be performed in aqueous solution, in organic solution or in the gas phase.

Biomolecules may be attached to the support either covalently or adsorptively. In a preferred embodiment of the invention the biomolecules are adsorptively attached to the activated surface 15 of the support. Preferably, the biomolecules are attached to the surface in spots, thereby forming a (micro)array of spots. A preferred method to spot the surface with biomolecules applies inkjet technology. This technology allows for the accurate deposition of defined volumes of liquid. (See e.g. T.P. Theriault: DNA diagnostic systems based on novel Chem-Jet technologies, IBC Conference on Biochip Array Technologies, Washington DC, May 10, 1995)

20 In a highly preferred embodiment of the invention an acidic solution of pH 5 is used for the preparation of APS-activated aluminium oxide porous membranes (which are electrochemically manufactured), spotted with arrays of oligonucleotides, which oligonucleotides are adsorptively attached to the activated surface.

25 Metal oxide supports prepared according to the method of the invention, are very useful for diagnostic purposes, for example in probe-based assays. In particular (micro)arrays, on the surface of which essentially no free amino groups are present that lead to a-specific binding, are very suitable for that purpose. In such arrays, the density of amino groups on the surface area 30 between the spots is significantly lower than the density of amino groups in the spots. Preferably, the arrays comprise different biomolecules in different spots, allowing multi-analyte

WO 01/12846

PCT/EP00/07736

detection. An analyte is a substance, usually a biomolecule, in a mixture which may be detected because of its capability to interact specifically with a selected reagents (for example another biomolecule capable of reacting with the analyte) (on a support).

Probe-based assays comprise for example nucleic acid hybridization assays and immunological assays. In such assays, a sample which comprises an analyte is contacted with a loaded support prepared according to the invention. The analyte is subsequently allowed to bind to the biomolecule which is attached to the surface of the support. Detection of binding can be performed by (1) adding a detection means, for example a substance capable of binding to the analyte, which substance is provided with a label, (2) allowing the detection means to bind to the complex of the analyte and the biomolecule, and (3) determining whether the label is present at the position where the biomolecule was attached. Alternatively, the analyte may already have been provided with a label, in which case binding to the biomolecule can be detected directly, without the addition of a detection means.

The present invention therefore also relates to a kit of parts comprising a metal oxide support according to the invention, further comprising a detection means for determining whether binding has occurred between the biomolecules and an analyte. Preferably, such detection means is a substance capable of binding to the analyte and being provided with a label. Such label is in particular useful, if it is capable of inducing a colour reaction and/or capable of bio- or chemo- or photoluminescence.

Biomolecules which may be used in the process of the invention include oligonucleotides and other negatively charged capture molecules, such as antibodies, antigens, peptides, receptors, haptens and ligands for receptors (which may be modified to introduce (additional) negative charges). Preferred are oligonucleotides. However, the scope of the invention is not limited to these specific molecules. The method may very well be useful to supports loaded with other types of molecules as well.

The invention is further illustrated by the following examples.

## EXAMPLES

### Preparation of APS-membranes:

5

Membranes (Anodisc 25, 0.2 um; Whatman) were silanated by placing them in a 1 % solution of 3-aminopropyltriethoxysilane (Acros, APS) in demineralised water (milliQ), for a period of 1 hr on a plateshaker. The membranes were soaked in water to remove the bulk of the APS molecules and subsequently washed individually by sucking 5 ml of milliQ through the membranes to remove the last traces of free APS. These membranes were heated for 2 hr's at 10 120 °C under vacuum. After cooling, these "APS-membranes" were stored in a vacuum desiccator, under argon over KOH until they were used.

### Stability study of APS-membranes:

15

The following buffers were made:

- 40 mM Acetate buffer pH 5.0; from sodiumacetate and acetic acid
- 40 mM Acetate buffer pH 6.0; from sodiumacetate and acetic acid
- 40 mM Phosphate buffer pH 7.0; from sodiumdihydrogenphosphate and NaOH
- 20 • 40 mM Borate buffer pH 8.0; from sodium tetraborate and hydrogen chloride
- 40 mM Borate buffer pH 9.0; from sodium tetraborate and hydrogen chloride

The APS membranes were incubated at the above mentioned pH's using the appropriate buffer for a period between 0.25 and 22 hr's (see table 1, for details). After this period the membrane was removed from the buffer solution and washed with milliQ and ethanol and dried under 25 vacuum at room temperature. Subsequently the amount of amino-groups was determined using a modified trinitrobenzenesulfonic acid (TNBS) method [Habeeb, A.F.S.A. (1996), Anal. Biochem. 14, 328. See also Sashidhar, R.B., Kapoor, A.K., Ramana, D., (1994), J. Immunol. Methods]. A commercially available stock solution (Sigma) of 5% (m/v) of TNBS was diluted 25-fold 30 with a 50 mM borate buffer of pH 10.0 directly before the amino-group determination was performed. Each treated membrane was placed individually in a beaker and 4 ml of the diluted

WO 01/12846

PCT/EP00/07736

8

TNBS solution was added and the membrane was incubated on a plateshaker for 1 hr at room temperature. The yellow/orange membranes were thoroughly washed (by using vacuum to suck liquids through the membrane) with milliQ to remove excess TNBS. Subsequently the membranes were dissolved in a known amount (e.g. 4.0 ml) of a 4.0 M NaOH solution in milliQ. After filtration of this solution over a 0.45 µm filter, the absorption was measured using an UV/vis spectrophotometer. Using the extinction coefficient of the adduct at 390 nm of 11929 l/mol/cm, the number of amino groups per membrane that reacted with TNBS could be determined. In table 1 the decrease (in %) in amino-groups as function of time and pH is given.

Time (hr)	Percentage of aminogroups at				
	pH 5.0	pH 6.0	pH 7.0	pH 8.0	pH 9.0
Blanc exp.	100	100	100	100	100
0.25	54				
0.5	19				
1	9				
1.5		49			
2.5		17	82	96	51
6			69	52	34
22			54	42	21

10 Table 1: degradation as function of pH and time of APS membranes

From this table it is clear that the loss of aminogroups is fastest at lower pH's.

#### Protective effects of loading of the activated surface of a support:

15

##### (a) Protective effect of the TNBS group:

20

In another experiment the aminogroups on an APS membrane reacted with TNBS as described above. This yielded membranes that contain covalently linked chromophores that consist of the trinitrobenzene adduct of the amino group (APS-TNB membranes).

WO 01/12846

PCT/EP00/07736

9

These membranes were treated with the same buffers mentioned above for a period of 22 hr's at room temperature. In table 2 the remaining amount of chromophores after this period, as determined with the above mentioned method, are summarized.

pH applied	Resulting aminogroups cq chromophores (%)
Blanc experiment	100
5.0	71
6.0	95
7.0	83
8.0	90
9.0	95

5 Table 2: stability of TNB-APS membranes

This table clearly shows, that functionalisation of the aminogroups results in a large increase of the stability. In other words, the majority of the functionalized aminogroups attached to the surface is not affected.

10

#### (b) Protective effect of DNA

A haring sperm DNA solution of 1 µg/ml in milliQ was prepared and 1 µl of this solution was pipetted onto the APS membranes in spots. These membranes were devided in two sets: one 15 which was treated with pH 5 buffer (for 1 hr) and the other which were not. Both sets of membranes were subsequently treated with TNBS (method described above) in order to detect any decrease in amino-groups. This yielded the following results. The total surface of the untreated membrane showed the expected orange colour since no degradation (removal) of APS groups had taken place. The surface of the membrane that was treated at pH 5.0 was not 20 orange but very slightly yellow, due to the degradation of nearly all APS molecules. However, at the spots where the DNA was pipetted on the membranc, an orange colour was still visible, indicating the protective effect of the DNA on the degradation process of the aminogroups on the surface. It was shown in a blanc experiment that the amino groups of DNA did not react

WO 01/12846

PCT/EP00/07736

10

with TNBS in such a way that this could explain the orange colour observed for the pH 5 treated membrane.

**(c) Protective effect of oligonucleotides**

5

A solution of 200uM oligonucleotide with the sequence 5'STAT GGC TCT CCC GGG AGGGGG GGT CCT GGA 3' was prepared. This solution was pipetted onto two unmodified membranes and onto two APS membranes. In this process only one half of every membrane was covered with the oligonucleotide. Subsequently these membranes were dried at 37 °C for 10 one hr. One unmodified and one APS membrane were treated with pH 5 solution as described above. Subsequently all membranes were washed with phosphate buffer pH 7.4 and ethanol and dried. All membranes were placed in the diluted TNBS solution as described above and incubated for one hr. After washing and drying, the unmodified membranes were totally white, while the total surface of the APS membrane that was not treated with pH 5 was yellow.

15

The pH 5 treated APS membrane showed a slightly yellow color on the half that was covered with the oligonucleotides while the other half was totally white.

This experiment clearly shows the protective effect of oligonucleotides.

**(d) Arrays of oligonucleotides:**

20

The protective effect was also visualised in a different way using hybridization of oligonucleotides:

Using a commercially available spotter (Packard instruments), droplets of 300 picoliter of oligonucleotide A (100 µM dissolved in milliQ) were spotted onto APS membranes:

25

This oligonucleotide A is defined by the sequence: 5'-TTG TAC AGA ACT GGA AAA GGA 3'. Also available for hybridization experiments is oligonucleotide B (sequence 5'-TCC TTT TCC AGT TCT GTA CAA 3') which is complementary to A and labeled with a fluoresceine moiety at the 5' end.

30

After spotting, all membranes were dried at 50 °C for 1 hr. One set of membranes was incubated in an acetate buffer (40 mM, pH 5.0) for 30 minutes and subsequently washed with

WO 01/12846

PCT/EP00/07736

11

milliQ, ethanol, and dried under vacuum. These membranes will be referred to as "pH 5 arrays". As a blanc experiment the other set of membranes was not treated with the pH 5.0 solution, but it was only washed with milliQ, ethanol and dried under vacuum. These membranes will be called "blanc array". All membranes were stored under argon until being used for hybridisation experiments.

The membranes were placed in a homebuilt device that allows 25 µl of a phosphate buffer (pH 7.0) containing the complementary oligonucleotide B being flushed back and forth through the membrane. If the solution is below this device, a hybridised nucleotide on the membrane can directly be seen due to its fluorescent label using an ordinary fluorescence microscope and a CCD-camera. With this setup, the data in table 3 have been collected. One cycle is defined as the 25 µl being pumped up and down one time through the membrane. Specific signals have been corrected for the background signal.

15

Cycles	Signal (arb.units) for pH 5 arrays		Cycles	Signal (arb.units) for blanc arrays	
	Specific	Background		Specific	Background
0	0	5	0	0	5
2	4	8	1	0	41
5	7	8	5	2	47
10	11	9			
15	13	9			
20	15	9			

Table 3: Specific and a-specific interactions of pH 5 arrays and blanc arrays

From this table the following observations are important:

20

- The background signal for pH 5 arrays is low and nearly constant
- The specific hybridisation for pH 5 arrays takes place rapidly and can easily be monitored

WO 01/12846

PCT/EP00/07736

12

- The blanc array does not show specific signals, due to a strong a-specific interaction between the amino-groups (which are present all over the membrane) and oligonucleotide B.
- The a-specific interactions (background) that are seen for the blanc arrays, is highly reduced by the acidic treatment.

5 Thus, this experiment shows that the acidic treatment removes all amino groups that are not covered and protected by oligonucleotides. Oligonucleotide A is not removed from the surface indicating that it is still captured by aminogroups on the surface below the nucleotides which  
10 have not been removed.

WO 01/12846

PCT/EP00/07736

13

CLAIMS

1. A method for the preparation of metal oxide supports loaded with biomolecules, comprising  
the steps of:
  - (a) activating the surface of the support by means of a silanating agent comprising an  
amine group;
  - (b) loading the support by attaching biomolecules to the activated surface,  
characterized in that subsequently the loaded support is treated with an acidic solution, and  
provided that the method is not used for the preparation of silica wafers which are aminated  
by silanation using (3-aminopropyl)monoethoxydimethylsilane and loaded with  
oligonucleotides.
2. A method for the preparation of metal oxide supports loaded with biomolecules, comprising  
the steps of:
  - (a) activating the surface of the support by means of a silanating agent comprising an  
amine group;
  - (b) loading the support by attaching biomolecules to the activated surface,  
characterized in that subsequently the loaded support is treated with a basic or neutral  
solution, and provided that the method is not used for derivatization of aluminiumoxide  
nanoparticles aminated with (3-aminopropyl)triethoxysilane, wherein the basic solution  
further contains a large excess of N-acetylhomocysteinelactone.
3. The method of claim 1, wherein the solution is of pH 2 to 7.
4. The method of claim 3, wherein the biomolecules are oligonucleotides and the pH is 4-5.
5. The method of claim 1, wherein the metal oxide support is a (electrochemically  
manufactured) porous metal oxide membrane.
6. The method of claim 5, wherein the metal oxide is aluminium oxide.

WO 01/12846

PCT/EP00/07736

14

7. The method of claim 1, wherein the support is activated by means of a silanating agent comprising an amine group selected from 3-aminopropyltriethoxysilane, 4-aminobutyl-dimethyl-methoxysilane, 3-[2-(2-aminoethylamino)ethylamino]propyl-trimethoxysilane, 3-(2-aminoethylamino)propyl-methyldimethoxysilane, 3-(2-aminoethylamino)propyl-trimethoxysilane, 3-aminopropyl-methyl-diethoxysilane, (3-aminopropyl)tris[2-(2-methoxyethoxy)ethoxy]silane and 4-aminobutyltriethoxysilane,

5

8. The method of claim 7, wherein the silanating agent comprising an amine group is 3-aminopropyltriethoxysilane.

10

9. The method of claim 8, wherein 3-aminopropyl triethoxysilane is used in an unbuffered aqueous solution.

15

10. The method of claim 1, wherein the biomolecules are adsorptively attached to the activated surface of the support.

11. The method of claim 1, wherein the biomolecules are attached to the activated surface in spots, thereby forming an array of spots.

20

12. The method of claim 11, wherein the biomolecules attached to the surface in different spots may be the same or different.

13. The method of claim 1, wherein the biomolecules are oligonucleotides.

25

14. A loaded metal oxide support prepared according to the method of claim 1.

15. An aminoalkyltrialkoxysilane-activated metal oxide support, provided with an array of spots of biomolecules attached to the support, characterized in that on the array the density of amino groups on the surface area between the spots is significantly lower than the density of amino groups in the spots.

30

WO 01/12846

PCT/EP00/07736

15

16. Use of the metal oxide support of claim 14 or 15 for performing a probe-based assay.
17. A kit of parts comprising the metal oxide support of claim 14 or 15, further comprising a detection means for determining whether binding has occurred between the biomolecules  
5 and an analyte.
18. A kit according to claim 17, wherein the detection means is a substance capable of binding to the analyte and being provided with a label.
- 10 19. A kit according to claim 18, wherein the label is capable of inducing a colour reaction and/or capable of bio-, chemo- or photoluminescence.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number  
**WO 01/12846 A1**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68,  
G01N 33/553 [NL/NL]; Fokke, Dode Nieuwstraat 58, NL-5211 Ek's  
Hertogenbosch (NL).

(21) International Application Number: PCT/EP00/07736 (74) Agent: HOGENBIRK, M.; P.O. Box 20, NL-5340 BH  
Oss (NL).

(22) International Filing Date: 9 August 2000 (09.08.2000)

(81) Designated States (national): AU, CA, ID, JP, KR, US,  
ZA.

(25) Filing Language: English

(84) Designated States (regional): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

(30) Priority Data:  
99202649.2 16 August 1999 (16.08.1999) EP

**Published:**


- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(71) Applicant (for all designated States except US): PAM-GENE B.V. [NL/NL]; Grote Gent 2, NL-5261 BT Vught (NL).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventor; and

(75) Inventor/Applicant (for US only): VENEMA F.



A1

(54) Title: PREPARATION OF METAL OXIDE SUPPORTS LOADED WITH BIOMOLECULES

(57) Abstract: The invention relates to method for the preparation of metal oxide supports loaded with biomolecules, comprising the steps of: (a) activating the surface of the support by means of a silanating agent comprising an amine group; (b) loading the support by attaching biomolecules to the activated surface, characterized in that subsequently the loaded support is treated with an acidic solution, and provided that the method is not used for the preparation of silica wafers which are aminated by silanation using (3-amino-prdeyl)monoethoxydimethylsilane and loaded with oligonucleotides. Similarly, an activated and loaded support may be treated with a basic or neutral solution, provided that the method is not used for derivatization of aluminiumoxide nanoparticles aminated with (3-aminopropyl)triethoxysilane, wherein the basic solution further contains a large excess of N-acetylhomocysteinolactone. This method can for example be used in the preparation of arrays for probe-based assays.

**WO 01/12846 A1**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)</b>		<b>Attorney Docket Number</b>	65959/16
		<b>First Named Inventor</b>	F. Venema
<b>COMPLETE IF KNOWN</b>			
		<b>Application Number</b>	10/049,804
		<b>Filing Date</b>	February 14, 2002
		<b>Art Unit</b>	to be assigned
		<b>Examiner Name</b>	to be assigned

As the below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original and first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**PREPARATION OF METAL OXIDE SUPPORTS LOADED WITH BIOMOLECULES**

*(Title of the Invention)*

the specification of which

is attached hereto

OR

was filed on (MM/DD/YYYY) 02/14/2002 as United States Application Number or PCT International

Application Number 10/049,804 and was amended on (MM/DD/YYYY)   (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	YES	NO
PCT/EP00/07736	PCT	08/09/2000	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
EP 99202649.2	Europe	08/16/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

[Page 1 of 2]

65959/19

PTO/SB/01 (10-01)

Approved for use through 10/31/2002, OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

Direct all correspondence to: <input checked="" type="checkbox"/> Customer Number or Bar Code Label		<input type="text"/>	OR <input type="checkbox"/> Correspondence address below
<p>Name <u>Kenneth P. George, Esq.</u></p> <p>Address <u>Amster, Rothstein &amp; Ebenstein</u></p> <p>City <u>90 Park Avenue</u></p> <p>State <u>New York</u></p> <p>ZIP <u>10016</u></p> <p>Country <u>USA</u></p> <p>Telephone <u>212-697-5995</u></p> <p>Fax <u>212-286-0854</u></p>			
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p>			
<p><b>NAME OF SOLE OR FIRST INVENTOR :</b> <input type="checkbox"/> A petition has been filed for this unsigned inventor</p>			
<p>Given Name (first and middle [if any]) <u>F.</u></p> <p>Inventor's Signature </p>		<p>Family Name <u>Venema</u></p> <p>Date <u>17<sup>th</sup> June 2002</u></p>	
<p>Residence: City <u>'s-Hertogenbosch</u></p>		<p>State <u>--</u></p>	<p>Kingdom of the Country <u>Netherlands</u></p>
<p>Mailing Address <u>Fokke, Dode Nieuwstraat 58, NL-5211 Ek</u></p>			
<p>City <u>'s-Hertogenbosch</u></p>		<p>State <u>--</u></p>	<p>ZIP <u>--</u></p>
<p>Country <u>Netherlands</u></p>			
<p><b>NAME OF SECOND INVENTOR:</b> <input type="checkbox"/> A petition has been filed for this unsigned inventor</p>			
<p>Given Name (first and middle [if any])</p>		<p>Family Name or Surname</p>	
<p>Inventor's Signature</p>		<p>Date</p>	
<p>Residence: City</p>		<p>State</p>	<p>Country</p>
<p>Citizenship</p>			
<p>Mailing Address</p>			
<p>City</p>		<p>State</p>	<p>ZIP</p>
<p>Country</p>			
<p><input type="checkbox"/> Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.</p>			

Please type a plus sign (+) inside this box → +

PTO/SB/81 (02-01)

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it display a valid OMB control number.

## POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	10/049,804
Filing Date	February 14, 2002
First Named Inventor	F. Venema
Title	Preparation of Metal Oxide Supports Loaded with Biomolecules
Group Art Unit	Not assigned
Examiner Name	Not assigned
Attorney Docket Number	65959/16

I hereby appoint:

Practitioners at Customer Number

Place Customer  
Number Bar Code  
Label here

OR

Practitioner(s) named below:

Name	Registration No.	Name	Registration No.
Morton Amster	16,677	Abraham Kasdan	32,997
Craig Arnold	34,287	Anthony F. Lo Cicero	29,403
Michael J. Berger	25,829	Ira E. Siffin	33,785
Daniel Ebenstein	24,932	Neil M. Zipkin	27,476
Kenneth P. George	130,259	Elie H. Gendloff	44,704
Philip H. Gottfried	25,871		

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

The above-mentioned Customer Number.

OR

Practitioners at Customer Number

Place Customer  
Number Bar Code  
Label here

OR

Firm or  
Individual Name

Kenneth P. George, Esq.

Address

AMSTER, ROTHSTEIN & EBENSTEIN

Address

90 Park Avenue

City

New York

State

New York

Zip

10016

Country

U.S.A.

Telephone

212-697-5995

Fax 212-286-0854

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

### SIGNATURE of Applicant or Assignee of Record

Name F. Venema

Signature

Date

17th June 2002


NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

\*Total of 1 forms are submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Rec'd PCT/INTO 26 JUL 2002

10/049804



65959-16-pam003pct.ST25  
SEQUENCE LISTING

<110> XAMGENE B.V.

Preparation of metal oxide supports loaded with biomolecules

<130> 65959/16

<140> 10/049,804  
<141> 2000-02-14

<150> EP 99202649.2  
<151> 1999-08-16

<160> 3

<170> PatentIn version 3.1

<210> 1  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<223> probe

<400> 1  
tatggctctc ccgggagggg gggtcctgga

30

<210> 2  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<223> probe

<400> 2  
ttgtacagaa ctggaaaagg a

21

<210> 3  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<223> probe

<400> 3  
tcctttcca gttctgtaca a

21